Ohio State Navbar

Research

John Harrison Howard, M.D.


410 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-7742

Email: howard.984@osu.edu

 

Current OSU Appointments

Assistant Professor-Clinical, Surgical Oncology

Physician, FGP-Surgical Oncology

 

Clinical Interest

Surgery

Licenses

2004 - present American Board Surgery Certificate: American Board of Surgery
 

Chapters in Books

Congenital and Acquired Disturbance of Breast Development and Growth

Mastectomy

Chest Wall Resection

Multi-Disciplinary Management of Retroperitoneal Sarcoma

 

Clinical Services

07/01/2014 Summer Scholar Surgical Oncology lecture (The Ohio State University Medical Center)
09/01/2015 Honors Surgery Lecture - Surgical Oncology (The Ohio State University Hospital)
11/01/2015 Professor's Conference (The Ohio State University Wexner Medical Center)

Clinical Trials

A PHASE III MULTICENTER RANDOMIZED TRIAL OF SENTINEL LYMPHADENECTOMY AND COMPLETE LYMPH NODE DISSECTION VERSUS SENTINEL LYMPHADENECTOMY ALONE IN CUTANEOUS MELANOMA PATIENTS WITH MOLECULAR OR HISTOPATHOLOGICAL EVIDENCE OF METASTASES IN THE SENTINEL NODE

DECISION IMPACT ANALYSIS OF FOUNDATION MEDICINE'S NEXT GENERATION SEQUENCING TEST IN ADVANCED SOLID TUMOR MALIGNANCIES

ECOG 1609: A PHASE III RANDOMIZED STUDY OF ADJUVANT IPILIMUMAB ANTI-CTLA4 THERAPY VERSUS HIGH-DOSE INTERFERON A-2B FOR RESECTED HIGH-RISK MELANOMA

ESTABLISHING CELL LINES AND EXAMINING TUMOR AND PERIPHERAL BLOOD FROM HUMAN SARCOMA AND OTHER SOFT TISSUE AND BONE TUMORS

SOFT TISSUE SARCOMA (STS) TREATED WITH RADIATION THERAPY: RETROSPECTIVE REVIEW OF CLINICAL AND DOSIMETRIC PARAMETERS THAT IMPACT LOCAL CONTROL, TOXICITY AND SURVIVAL

A STORAGE FACILITY FOR TISSUES OBTAINED FROM PATIENTS WITH MALIGNANT MELANOMA

ARST1321, PAZOPANIB NEOADJUVANT TRIAL IN NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS (PAZNTIS): A PHASE II/III RANDOMIZED TRIAL OF PREOPERATIVE CHEMORADIATION OR PREOPERATIVE RADIATION PLUS OR MINUS PAZOPANIB (NSC# 737754, IND# 118613)

ROLE OF ADJUVANT RADIATION THERAPY AFTER LYMPHADENECTOMY IN BRAF-MUTATED AND NRAS-MUTATED STAGE III MELANOMA VERSUS WILD-TYPE STAGE III MELANOMA

Retrospective Review of Piecemeal versus En Bloc Resection in Liposarcoma

OSU 15130: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 238)

A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma

An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry

A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC in stage III and stage IV (resected) melanoma to prevent recurrence

A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)

 

Conferences

microRNA Profiling of Distant Metastatic Melanoma

Plasma microRNA Dynamics Following Surgical Resection of Metastatic Melanoma

 

Degrees

1997 B.A., University of Virginia

2003 M.D., University of Alabama School of Medicine

 

Editorial Activities

2013 Journal of Surgical Oncology
2014 BMC
2015 Frontiers in Oncology and Surgery - Editorial Board of Surgical Oncology
 

Honors

2000 - present Peacock Fellow Gross Anatomy Teaching Assistant. Peacock Fellow Gross Anatomy.
2001 - present Letter of Commendation of Introduction to Clinical Medicine. Letter of Commendation of Introduction to Clinical Medicine.
2006 - 2007 Excellence in Basic Science Research Award. Excellence in Basic Science Research Award.
2007 - present Postdoctoral Career Enhancement Award. Postdoctoral Career Enhancement.
2014 - present National Top Patient Satisfaction Recognition. none.
 

Journal Articles

 

Presentations

Hypermethylation of MED-1 Tumor Suppressor Gene is Associated to Colorectal Cancer Progression

Hypermethylation and Supression of DNA Repair Gene MED 1 in Sporadic Human Colorectal Cancer.

Promoter Hypermethylation Leading to Inactivation of MED 1 DNA Repair Gene is Present in Human Colorectal and Ovarian Cancer.

Hypermethylation and Supression of DNA Repair Gene MED 1 in Sporadic Human Colorectal Cancer.

Epigenetic Downregulation of the DNA Repair Gene MED 1/MBD4 in Colorectal and Ovarian Cancer.

Radiofrequency Ablation for Unresectable Tumors of Liver

Surgical Resection for Melanoma Metastatic to Distant Sites: Data from two international, radomized, prospective trials.

Multiple Draining Lymph Node Basins in Melanoma: Friend or Foe?

Piecemeal Resection in Well-Differentiated and De-Differentiated Liposarcoma

Cae presentation with Professors and Fellows: 25 year old with thight mass on anticoagulation

 

Professional Activities

present Melanoma Patient Education Symposium: Current Surgical Therapy for Melanoma. Melanoma Research Foundation. Columbus, OH.
 

Unpublished Works

Abdominal Desmoid Fibromatosis

Multiple Draining Lymph Node Basins in Melanoma: Friend or Foe?